Five-year follow-up results from the phase 3 CheckMate-025 study, which compared nivolumab (Opdivo) with everolimus in previously treated advanced or metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend.
Nivolumab continues to show superior overall survival and objective response rates in patients with previously treated advanced or metastatic RCC compared to patients treated with everolimus. During a follow-up of 64 months, 26% of patients treated with nivolumab were alive compared to 18% of patients treated with everolimus. Additionally, objective response rates were 23% for nivolumab versus 4% for everolimus and the median duration of response was 18.2 months versus 14 months, respectively. Nivolumab was well tolerated with no new safety concerns or drug-related deaths occurred during the extended follow-up period compared to the original CheckMate-025 study.
“Five-year survival results from the CheckMate-025 study, along with the ongoing response rates observed in the trial, highlight the potential for long-term survival and efficacy of nivolumab monotherapy for patients with previously-treated advanced RCC,” said Dr Robert Motzer from Memorial Sloan Kettering Cancer Center in the USA. “These data represent the longest follow-up for a PD-1 immune checkpoint inhibitor in this setting and underscore the potential increased survival rates nivolumab can deliver for patients with advanced RCC who have received prior anti-angiogenic therapy.”